This Type of Cholesterol Is a Risk Factor for Heart Disease. Emerging Drugs from Lilly and Amgen Could Treat It.
About a quarter of people risk heart attacks and strokes because they inherited a kind of cholesterol that statin drugs can’t ...
Amgen (NasdaqGS:AMGN) Gains FDA Approval For UPLIZNA In Treating IgG4-Related Disease
Amgen (NasdaqGS:AMGN) experienced a significant 18.62% price increase over the last quarter, coinciding with the recent FDA ...
US FDA approves Amgen's Uplizna as first treatment for rare immune disorder
The U.S. Food and Drug Administration has approved expanded use of Amgen's drug, Uplizna, to help reduce the risk of flares ...
Fierce Pharma2d
Amgen wins key rare disease nod for Uplizna, checking off one goal in expansion push
With a label expansion for Uplizna pushing the drug into an untouched rare disease market, Amgen is getting its money’s worth ...
BioSpace2d
Amgen Wins Expansion for Uplizna as First Drug for IgG4-Related Disease
The FDA approved Amgen ’s anti-CD19 therapy Uplizna Thursday for use in patients with IgG4-related disease. Uplizna is the ...
Q4 Earnings Outperformers: Amgen (NASDAQ:AMGN) And The Rest Of The Therapeutics Stocks
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take ...
Explore more
Amgen Inc. stock underperforms Thursday when compared to competitors despite daily gains
Shares of Amgen Inc. AMGN rallied 1.36% to $309.85 Thursday, on what proved to be an all-around dismal trading session for ...
Amgen: Excellent Buy And Hold For A Volatile Market
Amgen is a leading biopharmaceutical company that develops innovative medicines in areas with significant unmet needs. Read ...
Amgen, Sabra Health Care And A Financial Stock On CNBC's 'Final Trades'
On CNBC's “ Halftime Report Final Trades ,” Jenny Van Leeuwen Harrington of Gilman Hill Asset Management, LLC said Sabra ...
Judge throws out lawsuit challenging Colorado’s ability to cap prices on prescription drugs
A federal judge has thrown out Amgen’s lawsuit against the state board empowered to set price ceilings on prescription drugs ...
FDA Approves Amgen's Uplizna As First Drug For Chronic Immune-Mediated Fibroinflammatory Disorder
The FDA approved Amgen's Uplizna as the first treatment for IgG4-RD. The decision is backed by the MITIGATE trial, showing reduced flares and sustained efficacy.
Amgen gets expanded FDA label approval for Uplizna
Amgen (NASDAQ: NASDAQ:AMGN) announced that the U.S. Food and Drug Administration (FDA) has granted an expanded label approval ...